<DOC>
	<DOCNO>NCT00031694</DOCNO>
	<brief_summary>Phase II trial study effectiveness combine paclitaxel bryostatin-1 treating patient locally advance unresectable metastatic pancreatic cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Bryostatin-1 may help paclitaxel kill cancer cell make tumor cell sensitive drug .</brief_summary>
	<brief_title>Paclitaxel Bryostatin 1 Treating Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine response rate weekly , sequential paclitaxel/ bryostatin-1 patient unresectable metastatic pancreatic cancer . II . To determine toxicity therapy . III . To determine patient survival therapy . IV . To determine Bryostatin-1 pharmacokinetics . OUTLINE : This open-label , multicenter study . Patients receive paclitaxel IV 1 hour day 1 follow bryostatin 1 IV 1 hour day 2 week 1-3 . Courses repeat every 4 week absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Acinar Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologic proof adenocarcinoma pancreas locally advance consider surgically resectable metastatic Patients without prior treatment eligible treatment protocol ; prior treatment may include one treatment course chemo/RT and/ one course chemotherapy , two prior course chemotherapy ; Measurable disease ECOG performance status 01 Ability sign inform consent form indicate awareness investigational nature study , keep policy hospital Patients may receive concurrent chemotherapy , immunotherapy , radiotherapy ; recent treatment pancreatic cancer , within limitation allow prior therapy must 28 day longer prior enrollment study Absolute granulocytes &gt; 1,500/mm^3 Platelets &gt; 150,000/mm^3 Serum bilirubin &lt; 1.5 mg/dl Serum creatinine &lt; 1.5 mg/dl Presence ongoing toxic effect prior treatment Brain metastases History active angina myocardial infarction within 6 month ; history significant ventricular arrhythmia require medication antiarrhythmic ; well control atrial fibrillation standard management permit Pregnant lactate woman Preexisting neurotoxicity grade 3+ great Serious intercurrent infection , nonmalignant medical illness uncontrolled whose control may jeopardize complication therapy Psychiatric disorder render patient incapable comply requirement protocol HIV infection Any medical condition reason , investigator 's opinion , make patient unsuitable participate clinical trial ( example history prior poor compliance treatment )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>